Moreover, a phase II clinical trial combining alectinb with bevacizumab in ALK-positive non-squamous NSCLC patients with alectinib resistance showed clinical efficacy and acceptable toxicity in vivo [37]. This evidence concerns the gene ALK and non-small cell lung carcinoma.